International Multicentric Observational Study to Characterize Subpopulations of Patients with Autism Spectrum Disorder

Description

To determine sufficient number of biological and clinical markers to identify subgroups of potential best responders to a specific medication

Conditions

Autism Spectrum Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

To determine sufficient number of biological and clinical markers to identify subgroups of potential best responders to a specific medication

International, Multicentric, Observational Study to Characterize Subpopulations of Patients with Autism Spectrum Disorder

International Multicentric Observational Study to Characterize Subpopulations of Patients with Autism Spectrum Disorder

Condition
Autism Spectrum Disorder
Intervention / Treatment

-

Contacts and Locations

Phoenix

SARRC, Phoenix, Arizona, United States, 85006

Sherman Oaks

California Neuroscience Research, Sherman Oaks, California, United States, 91403

Miami Lakes

The Angel Medical Research, Miami Lakes, Florida, United States, 33016

Miami

BioPhase Research, Miami, Florida, United States, 33137

Chicago

Rush University Medical Center, Chicago, Illinois, United States, 60612

Columbia

University of Missouri, Thompson Center for Autism & Neurodevelopmental Disorders, Columbia, Missouri, United States, 65211

Alamogordo

Golden Hearts Diagnostic, Alamogordo, New Mexico, United States, 88210

Houston

Red Oak Psychiatry Associates, Houston, Texas, United States, 77090

Clinton

Alpine Research Organization, Clinton, Utah, United States, 84015

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants previously diagnosed with ASD (DSM-5)
  • * Available well-documented health records within the first 2 years of life
  • * Participants must have a parent or reliable caregiver who agrees to provide information about the participant
  • * Participants willing and consenting or assenting to participate.
  • * Episode of fever (i.e. ≥100.5 °F or ≥ 38 °C) or clinically significant illness without fever (as judged by the investigator), within 10 days before any study assessment.
  • * If the investigator assesses any unwillingness or any medical condition that may prevent the subject from completing this study.

Ages Eligible for Study

12 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Stalicla SA,

Paulo Fontoura, MD, PhD, STUDY_DIRECTOR, Stalicla SA

Study Record Dates

2025-12-31